Researchers estimated a low excess risk of prostate cancer death for favorable-risk patients undergoing active surveillance rather than surgery: 1.1% to 8.7% over 15 years.
Two-year prostate cancer survival rates only increased from 60% in 2004 to 63% in 2014.
In a study of men with bone metastases from metastatic castration-resistant prostate cancer, black men had no significantly greater risk of skeletal-related events than nonblack men.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Post hoc analysis of the PROMIS cohort shows that tumors undetected by mpMRI are smaller and of lower grade than those that are detected.
Has PSA screening led to overdiagnosis and overtreatment of a condition that may not actually cause any symptoms or lead to death?
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Men with metastatic castration-resistant prostate cancer and symptomatic bone metastases had longer survival times when they received radium-223 as first-line therapy compared with those who received the drug as third-line therapy.
A trial in phase 2 metastatic prostate cancer shows that some patients likely to benefit from ipilimumab treatment, even with low number of tumor mutations.
Olaparib prolonged progression-free survival compared with abiraterone or enzalutamide in a phase 3 trial of men with metastatic castration-resistant prostate cancer who had certain DNA repair mutations and whose disease was progressing while receiving novel hormonal therapy.
